148 related articles for article (PubMed ID: 27449794)
1. The Role of Size in Development of Mucosal Liposome-Lipopeptide Vaccine Candidates Against Group A Streptococcus.
Ghaffar KA; Marasini N; Giddam AK; Batzloff MR; Good MF; Skwarczynski M; Toth I
Med Chem; 2016; 13(1):22-27. PubMed ID: 27449794
[TBL] [Abstract][Full Text] [Related]
2. Liposome-based intranasal delivery of lipopeptide vaccine candidates against group A streptococcus.
Ghaffar KA; Marasini N; Giddam AK; Batzloff MR; Good MF; Skwarczynski M; Toth I
Acta Biomater; 2016 Sep; 41():161-8. PubMed ID: 27063491
[TBL] [Abstract][Full Text] [Related]
3. Structure-activity relationship for the development of a self-adjuvanting mucosally active lipopeptide vaccine against Streptococcus pyogenes.
Zaman M; Abdel-Aal AB; Fujita Y; Ziora ZM; Batzloff MR; Good MF; Toth I
J Med Chem; 2012 Oct; 55(19):8515-23. PubMed ID: 22974133
[TBL] [Abstract][Full Text] [Related]
4. Intranasal administration is an effective mucosal vaccine delivery route for self-adjuvanting lipid core peptides targeting the group A streptococcal M protein.
Olive C; Sun HK; Ho MF; Dyer J; Horváth A; Toth I; Good MF
J Infect Dis; 2006 Aug; 194(3):316-24. PubMed ID: 16826479
[TBL] [Abstract][Full Text] [Related]
5. Lipid core peptide/poly(lactic-co-glycolic acid) as a highly potent intranasal vaccine delivery system against Group A streptococcus.
Marasini N; Khalil ZG; Giddam AK; Ghaffar KA; Hussein WM; Capon RJ; Batzloff MR; Good MF; Skwarczynski M; Toth I
Int J Pharm; 2016 Nov; 513(1-2):410-420. PubMed ID: 27659862
[TBL] [Abstract][Full Text] [Related]
6. Double adjuvanting strategy for peptide-based vaccines: trimethyl chitosan nanoparticles for lipopeptide delivery.
Marasini N; Giddam AK; Khalil ZG; Hussein WM; Capon RJ; Batzloff MR; Good MF; Toth I; Skwarczynski M
Nanomedicine (Lond); 2016 Dec; 11(24):3223-3235. PubMed ID: 27830630
[TBL] [Abstract][Full Text] [Related]
7. Immunological evaluation of lipopeptide group A streptococcus (GAS) vaccine: structure-activity relationship.
Zaman M; Abdel-Aal AB; Fujita Y; Phillipps KS; Batzloff MR; Good MF; Toth I
PLoS One; 2012; 7(1):e30146. PubMed ID: 22253911
[TBL] [Abstract][Full Text] [Related]
8. Prime-Pull Immunization with a Bivalent M-Protein and Spy-CEP Peptide Vaccine Adjuvanted with CAF®01 Liposomes Induces Both Mucosal and Peripheral Protection from
Ozberk V; Reynolds S; Huo Y; Calcutt A; Eskandari S; Dooley J; Mills JL; Rasmussen IS; Dietrich J; Pandey M; Good MF
mBio; 2021 Feb; 12(1):. PubMed ID: 33622722
[TBL] [Abstract][Full Text] [Related]
9. Multilayer engineered nanoliposomes as a novel tool for oral delivery of lipopeptide-based vaccines against group A Streptococcus.
Marasini N; Giddam AK; Ghaffar KA; Batzloff MR; Good MF; Skwarczynski M; Toth I
Nanomedicine (Lond); 2016 May; 11(10):1223-36. PubMed ID: 27077314
[TBL] [Abstract][Full Text] [Related]
10. Design of three-component vaccines against group A streptococcal infections: importance of spatial arrangement of vaccine components.
Abdel-Aal AB; Zaman M; Fujita Y; Batzloff MR; Good MF; Toth I
J Med Chem; 2010 Nov; 53(22):8041-6. PubMed ID: 21028828
[TBL] [Abstract][Full Text] [Related]
11. Activity Relationship of Poly(ethylenimine)-Based Liposomes as Group A
Jin S; Zhang J; Nahar UJ; Huang W; Alharbi NA; Shalash AO; Koirala P; Yang J; Kiong JJE; Khalil ZG; Capon RJ; Stephenson RJ; Skwarczynski M; Toth I; Hussein WM
ACS Infect Dis; 2023 Aug; 9(8):1570-1581. PubMed ID: 37489053
[TBL] [Abstract][Full Text] [Related]
12. Structure-activity relationship of a series of synthetic lipopeptide self-adjuvanting group a streptococcal vaccine candidates.
Abdel-Aal AB; Batzloff MR; Fujita Y; Barozzi N; Faria A; Simerska P; Moyle PM; Good MF; Toth I
J Med Chem; 2008 Jan; 51(1):167-72. PubMed ID: 18072728
[TBL] [Abstract][Full Text] [Related]
13. Intranasal vaccination with a lipopeptide containing a conformationally constrained conserved minimal peptide, a universal T cell epitope, and a self-adjuvanting lipid protects mice from group A streptococcus challenge and reduces throat colonization.
Batzloff MR; Hartas J; Zeng W; Jackson DC; Good MF
J Infect Dis; 2006 Aug; 194(3):325-30. PubMed ID: 16826480
[TBL] [Abstract][Full Text] [Related]
14. Group A Streptococcal vaccine candidate: contribution of epitope to size, antigen presenting cell interaction and immunogenicity.
Zaman M; Chandrudu S; Giddam AK; Reiman J; Skwarczynski M; McPhun V; Moyle PM; Batzloff MR; Good MF; Toth I
Nanomedicine (Lond); 2014 Dec; 9(17):2613-24. PubMed ID: 25529566
[TBL] [Abstract][Full Text] [Related]
15. Polyethylenimine: An Intranasal Adjuvant for Liposomal Peptide-Based Subunit Vaccine against Group A
Dai CC; Yang J; Hussein WM; Zhao L; Wang X; Khalil ZG; Capon RJ; Toth I; Stephenson RJ
ACS Infect Dis; 2020 Sep; 6(9):2502-2512. PubMed ID: 32786276
[TBL] [Abstract][Full Text] [Related]
16. Structure-activity relationship of lipopeptide Group A streptococcus (GAS) vaccine candidates on toll-like receptor 2.
Zaman M; Abdel-Aal AM; Phillipps KSM; Fujita Y; Good MF; Toth I
Vaccine; 2010 Mar; 28(10):2243-2248. PubMed ID: 20045502
[TBL] [Abstract][Full Text] [Related]
17. Bivalent mucosal peptide vaccines administered using the LCP carrier system stimulate protective immune responses against Streptococcus pyogenes infection.
Schulze K; Ebensen T; Chandrudu S; Skwarczynski M; Toth I; Olive C; Guzman CA
Nanomedicine; 2017 Nov; 13(8):2463-2474. PubMed ID: 28887213
[TBL] [Abstract][Full Text] [Related]
18. Polyglutamic acid-trimethyl chitosan-based intranasal peptide nano-vaccine induces potent immune responses against group A streptococcus.
Nevagi RJ; Khalil ZG; Hussein WM; Powell J; Batzloff MR; Capon RJ; Good MF; Skwarczynski M; Toth I
Acta Biomater; 2018 Oct; 80():278-287. PubMed ID: 30266637
[TBL] [Abstract][Full Text] [Related]
19. Self-adjuvanting modular virus-like particles for mucosal vaccination against group A streptococcus (GAS).
Rivera-Hernandez T; Hartas J; Wu Y; Chuan YP; Lua LH; Good M; Batzloff MR; Middelberg AP
Vaccine; 2013 Apr; 31(15):1950-5. PubMed ID: 23422147
[TBL] [Abstract][Full Text] [Related]
20. A vaccine against S. pyogenes: design and experimental immune response.
Guilherme L; Postol E; Freschi de Barros S; Higa F; Alencar R; Lastre M; Zayas C; Puschel CR; Silva WR; Sa-Rocha LC; Sa-Rocha VM; Pérez O; Kalil J
Methods; 2009 Dec; 49(4):316-21. PubMed ID: 19409999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
